Do you want to read an article? Please log in or register.
Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial
Diabetes - GeneralType 2 Diabetes
Related content
Diabetes - GeneralType 2 Diabetes
Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International Insights from the TECOS Trial
Circulation.
Pagidipati NJ, Navar AM, Pieper KS, Green JB, Bethel MA, Armstrong PW, Josse RG, McGuire DK, Lokhnygina Y, Cornel JH, Halvorsen S, Strandberg TE, Delibasi T, Holman RR, Peterson ED; TECOS Study Group
doi: 10.1161/CIRCULATIONAHA.
Diabetes - GeneralType 2 Diabetes
Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial
JAMA Cardiol.
Scirica BM, Mosenzon O, Bhatt DL, Udell JA, Steg PG, McGuire DK, Im K, Kanevsky E, Stahre C, Sjöstrand M, Raz I, Braunwald E
doi: 10.1001/
COMMENTED
Type 2 Diabetes
Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Circulation.
Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR
doi: 10.1161/CIRCULATIONAHA.
Diabetes - GeneralType 2 Diabetes
The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
Diabetes Care.
Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, Stellfeld M, Tornøe K, Pratley RE; LEADER Publication Committee on behalf of the LEADER Trial Investigators
doi: 10.2337/dc18-1094.
COMMENTED
Type 2 Diabetes
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Lancet Diabetes Endocrinol.
Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I
doi: 10.1016/S2213-8587
COMMENTED
Type 2 Diabetes
Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
doi: 10.2337/dc19-2116.
COMMENTED
Type 2 Diabetes
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Lancet.
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS
doi: 10.1016/S0140-6736
Type 2 Diabetes
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial
JAMA.
Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, Pfarr E, Keller A, Mattheus M, Baanstra D, Meinicke T, George JT, von Eynatten M, McGuire DK, Marx N, CAROLINA Investigators.
doi: 10.1001/jama.2019.13772.
Type 2 Diabetes
Cumulative Risk of End-Stage Renal Disease Among Patients With Type 2 Diabetes: A Nationwide Inception Cohort Study
Diabetes Care.
Finne P, Groop PH, Arffman M, Kervinen M, Helve J, Grönhagen-Riska C, Sund R
doi: 10.2337/dc18-1485.